Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.35 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469208 | 0.77 | SLC7A5 (0.35) | — | |
| SCHEMBL24823223 | 0.75 | LOXL2 (0.36) | KAT2B | |
| SCHEMBL18571382 | 0.75 | HDAC6 (0.42) | HDAC6ADRB2ADRB1ADRB3P4HTM | |
| SCHEMBL17080194 | 0.75 | KAT2B (0.31) | KAT2B | |
| SCHEMBL20751484 | 0.71 | HDAC6 (0.39) | HDAC6 | |
| SCHEMBL20275214 | 0.71 | RXRA (0.45) | RXRARXRBRXRGFFAR1 | |
| SCHEMBL25219340 | 0.71 | SMN1; SMN2 (0.41) | ADRB2ADRB1ADRB3 | |
| SCHEMBL18667224 | 0.70 | KAT2B (0.40) | KAT2BCYP2C9 | |
| SCHEMBL18641539 | 0.70 | CYP1A2 (0.40) | KAT2BCYP2C9 | |
| SCHEMBL22652851 | 0.70 | LTB4R (0.44) | HDAC6KAT2BFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3336103-B1 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2020227105-A1 | ANTI-BCMA ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-3055298-B1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-3505534-A1 | ANTIBODIES COMPRISING SITESPECIFIC NONNATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | Sutro Biopharma, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2890402-B1 | MODIFIED AMINO ACIDS COMPRISING AN AZIDO GROUP | SUTRO BIOPHARMA INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2859017-B1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3336103-A1 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | Sutro Biopharma, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2015054658-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |